TEVA PHARMACEUTICAL INDUSTRIES LIMITED Cash Flows Between Transferor and Transferee, Beneficial Interest
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Cash Flows Between Transferor and Transferee, Beneficial Interest of $1.37 billion for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-01.
Discontinued › Notes
us-gaap:CashFlowsBetweenTransferorAndTransfereeBeneficialInterest · last filed 2018-11-01
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED cash flows between transferor and transferee, beneficial interest for the quarter ending 2018-09-30 was $402.00M, a 24.84% increase year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED cash flows between transferor and transferee, beneficial interest for the quarter ending 2018-06-30 was $526.00M, a 71.90% increase year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED cash flows between transferor and transferee, beneficial interest for the quarter ending 2018-03-31 was $444.00M, a 32.93% increase year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED cash flows between transferor and transferee, beneficial interest for the quarter ending 2017-09-30 was $322.00M.
| Period end | Cash Flows Between Transferor and Transferee, Beneficial Interest 3 month | Cash Flows Between Transferor and Transferee, Beneficial Interest 6 month | Cash Flows Between Transferor and Transferee, Beneficial Interest 9 month |
|---|---|---|---|
| 2018-09-30 | $402.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $928.00M derived: sum of 2 quarters · filed 2018-11-01 | $1.37B 10-Q · filed 2018-11-01 |
| 2018-06-30 | $526.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $970.00M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $444.00M 10-Q · filed 2018-05-03 | ||
| 2017-09-30 | $322.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $628.00M derived: sum of 2 quarters · filed 2018-11-01 | $962.00M 10-Q · filed 2018-11-01 |
| 2017-06-30 | $306.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $640.00M 10-Q · filed 2018-08-02 | |
| 2017-03-31 | $334.00M 10-Q · filed 2018-05-03 |